Mangoceuticals, Inc. (MGRX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Mangoceuticals, Inc. (MGRX) Healthcare & Pipeline Overview

Mangoceuticals, Inc. leverages telemedicine to provide innovative men's wellness solutions, focusing on erectile dysfunction products marketed under the Mango brand, positioning itself in a growing healthcare niche with a direct-to-consumer approach.

What Is the Investment Thesis for MGRX?

Mangoceuticals, Inc. operates in a niche market with significant growth potential, particularly in men's wellness and erectile dysfunction treatments. The telemedicine platform provides a unique value proposition, allowing for direct consumer engagement and streamlined service delivery. Given the increasing prevalence of erectile dysfunction and the growing acceptance of telehealth, Mangoceuticals is positioned to capture a substantial share of this market. The company's gross margin stands at 52.4%, indicating strong pricing power and operational efficiency, although it currently faces challenges with a profit margin of -4632.9%. As the telemedicine sector continues to expand, Mangoceuticals has the opportunity to enhance its product offerings and scale its operations, potentially leading to improved financial performance in the coming years.

Based on FMP financials and quantitative analysis

MGRX Key Highlights

Market Cap: $6.63M reflecting early-stage growth potential.

• Profit Margin: -4632.9%, indicating current operational challenges.
• Gross Margin: 52.4%, showcasing strong product pricing capabilities.
• Beta: 2.12, suggesting higher volatility compared to the market.
• Employee Count: 3, indicating a lean operational structure.

Who Are MGRX's Competitors?

MGRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MGRX's Key Strengths?

Innovative telemedicine platform enhances customer accessibility.

• Strong brand focus on men's wellness products.
• High gross margin reflects effective pricing strategies.

What Are MGRX's Weaknesses?

Small employee base may limit operational capacity.

• Negative profit margin indicates current financial challenges.
• Limited product range may restrict market appeal.

What Could Drive MGRX Stock Higher?

Expansion of product offerings to include additional men's wellness solutions.

• Increasing adoption of telehealth services enhancing customer engagement.
• Strategic marketing campaigns aimed at raising brand awareness.

What Are the Key Risks for MGRX?

Financial-distress signal — its Altman Z-Score of -5.42 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $4.9M recently.
• Regulatory challenges impacting product approvals and market entry.
• Competition from established players in the telehealth and wellness sectors.
• Economic downturns affecting consumer spending on wellness products.

What Are the Growth Opportunities for MGRX?

• Expansion of Product Line: Mangoceuticals can diversify its offerings by introducing additional men's wellness products, such as supplements and lifestyle aids. The global men's health market is projected to reach $4.5 billion by 2027, providing a substantial opportunity for growth.
• Increasing Telehealth Adoption: As telehealth becomes more mainstream, Mangoceuticals can capitalize on this trend by enhancing its digital platform and marketing strategies. The telemedicine market is expected to grow at a CAGR of 37.7% from 2021 to 2028, indicating a favorable environment for expansion.
• Strategic Partnerships: Collaborating with healthcare providers and pharmacies can enhance Mangoceuticals' distribution channels, improving product accessibility. Partnerships can also bolster credibility and brand recognition in a competitive market.
• Targeted Marketing Campaigns: By leveraging digital marketing strategies, Mangoceuticals can effectively reach its target demographic, increasing brand awareness and customer acquisition. The digital advertising market in healthcare is projected to grow significantly, providing a fertile ground for targeted campaigns.
• International Market Entry: Exploring opportunities in international markets where men's wellness products are in demand can provide Mangoceuticals with new revenue streams. Expanding into regions with growing healthcare access and telemedicine acceptance can enhance the company's market presence.

What Threats Does MGRX Face?

• Intense competition from established healthcare providers.
• Regulatory challenges in the healthcare sector.
• Market volatility may impact financial stability.

What Are MGRX's Competitive Advantages?

• Telemedicine platform provides a unique customer engagement model.
• Focus on men's wellness creates a specialized market niche.
• Strong gross margins indicate effective pricing strategies.

What Does MGRX Do?

Mangoceuticals, Inc., incorporated in 2021, is headquartered in Dallas, Texas, and operates as a subsidiary of Cohen Enterprises, Inc. The company specializes in developing, marketing, and selling men's wellness products, primarily targeting erectile dysfunction through its telemedicine platform. By utilizing an online sales strategy via its website, mangorx.com, Mangoceuticals aims to reach a broad audience seeking discreet and accessible healthcare solutions. The company's product offerings are designed to address a significant and growing market need for men's health, particularly in the realm of sexual wellness. With a small team of three employees, Mangoceuticals emphasizes efficiency and innovation in its operations, aiming to carve out a niche in the competitive healthcare information services sector. The company's focus on telemedicine aligns with broader trends in healthcare towards digital solutions, providing convenience and privacy for its customers. As it continues to grow, Mangoceuticals is positioned to capitalize on the increasing acceptance of telehealth services and the rising demand for men's wellness products.

What Products and Services Does MGRX Offer?

• Develops and markets men's wellness products.
• Offers erectile dysfunction treatments under the Mango brand.
• Utilizes a telemedicine platform for product distribution.
• Sells products directly to consumers via its website, mangorx.com.
• Focuses on providing discreet and accessible healthcare solutions.
• Operates as a subsidiary of Cohen Enterprises, Inc.

How Does MGRX Make Money?

• Generates revenue through the sale of men's wellness products online.
• Utilizes telemedicine to enhance customer engagement and service delivery.
• Focuses on direct-to-consumer sales to maximize margins.
• Leverages digital marketing to reach target demographics effectively.

What Industry Does MGRX Operate In?

The healthcare information services industry is experiencing robust growth, driven by the increasing adoption of telemedicine and digital health solutions. The market for men's wellness products, particularly erectile dysfunction treatments, is expanding as societal attitudes shift towards more open discussions about sexual health. Mangoceuticals, Inc. is positioned within this evolving landscape, competing with established players while leveraging its telemedicine platform to offer unique products directly to consumers. The industry is projected to grow significantly, with telehealth services expected to reach a market size of over $250 billion by 2027, providing ample opportunities for companies like Mangoceuticals.

Who Are MGRX's Key Customers?

• Men seeking solutions for erectile dysfunction.
• Individuals interested in wellness products focused on sexual health.
• Consumers preferring discreet online purchasing options.

Company Profile

Mangoceuticals, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO Jacob D. Cohen. MGRX has traded publicly since 2023.

Mangoceuticals, Inc. Financial Trajectory

Mangoceuticals, Inc. (MGRX) reported $69K in revenue for Q2 FY2026, reflecting 1.3% growth compared to the prior quarter. The company recorded a net loss of $1.3M, with diluted EPS of $-0.09. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MGRX averaged $-0.29 in diluted EPS.

How Mangoceuticals, Inc. Is Valued

Mangoceuticals, Inc. carries a market capitalization of $6.63M, placing it in the micro-cap category. Relative to its peer group, MGRX's quantitative score of 19/100 is below the peer average of 51/100.

Mangoceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.42 places it in the distress zone, a signal of elevated financial risk.

Over the past six months, Mangoceuticals, Inc. insiders filed 6 SEC Form 4 transactions — 3 sales and 3 purchases. Buying and selling roughly offset over the period, so insider signaling is neutral.

MGRX Financials

MGRX Latest News

MGRX Analyst Consensus

MGRX MoonshotScore

MGRX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources